Effects of Combination Therapy With Olmesartan and Azelnidipine on Serum Osteoprotegerin in Patients With Hypertension

Introduction

Arteriosclerosis is often complicated by vascular calcification, an important factor contributing to the onset and progression of cardiovascular diseases as well as an independent predictive factor for plaque instability and cardiovascular events. ¹ Vascular calcification was formerly regarded as only a part of the developmental process of arteriosclerosis and to be characteristic of advanced aging; however, recent studies have shown that calcification is caused by changes in vascular wall cells and the extracellular matrix. ² Currently, vascular calcification is regarded as a treatment target. However, no effective treatment approach has as yet been established for vascular calcification and this may reduce the efficacy of other cardiovascular treatments such as coronary intervention. Serum osteoprotegerin (OPG), ³ a bone turnover marker involved in coronary calcification and atheroma formation, is thought to be a useful serum marker of vascular calcification.

The combination of an angiotensin receptor blocker (ARB), a diuretic-antihypertensive, and a calcium-channel blocker (CCB) or concurrent uses of an ARB and a combination drug are anticipated to become the standard treatment for hypertension. However, the ARB/diuretic combination and the ARB/CCB combination have not been directly compared in the changes of bone-related markers in a clinical study. The purposes of this study are to investigate the effects of ARB/CCB versus ARB/diuretic combination on bone turnover markers, inflammation, and arteriosclerosis.

Methods

Our study included 48 patients with hypertension, 32 men and 16 women, all at least 20 years of age, who had been given olmesartan monotherapy (20.0 mg once-daily) at our outpatient clinic and had failed to satisfy antihypertensive criteria after 8 weeks of treatment. Hypertension was defined as 2 or more systolic blood pressure (SBP) measurements more than 140 mm Hg and/or diastolic blood pressure (DBP) more than 90 mm Hg, or documented hypertension currently treated with antihypertensives. All antihypertensive therapies used by the enrolled patients had initially been switched to olmesartan monotherapy. Patients were excluded from the study if their SBP exceeded 200 mm Hg and/or DBP exceeded 115 mm Hg. Patients with 2 or more SBP measurements more than 140 mm Hg and/or DBP measurements more than 90 mm Hg, after 8 weeks of olmesartan monotherapy, were included in the analysis. The exclusion criteria were secondary hypertension, arrhythmias, currently being treated for congestive heart failure, peripheral artery disease (ankle-brachial index of lower than 0.9), cardiovascular diseases (those with previously treated angina pectoris or myocardial infarction, those with reproducible chest pain on exercise, or those with chest pain at rest), clinically significant valvular disease, renal dysfunction (serum creatinine > 2.0 mg/dL), hyperkalemia, serious hepatic dysfunction, cancer, connective tissue disease, severe infection, being perioperative, serious trauma, hypersensitivity to any ingredients of the study drugs, confirmed or possible pregnancy, and being otherwise considered ineligible by the primary physician. The study was approved by the institutional review board of University of Fukui. All patients were fully informed of the study objectives and methods and consented to participate.

Patients with 2 or more nonconsecutive outpatient SBP of 140 mm Hg or higher and/or DBP of 90 mm Hg or higher were included in the analysis of data from this prospective, randomized, investigator-blinded, open-label, controlled study. The patients were assigned to receive olmesartan plus azelnidipine (O/A) 16 mg or olmesartan plus indapamide (O/D) 1 mg for 12 months. Azelnidipine is retained in the vascular wall due to its high lipophilicity; its efficacy for vascular remodeling is superior to that of other calcium channel antagonists. ⁴ Similarly in the diuretics selection; we chose “indapamide” for the control medicine, since indapamide exerts antioxidative, antiatherogenic actions, and enhances endothelial function compared to other diuretic-antihypertensive medications. ⁵ Changing the doses of study drugs was not allowed.

The doses of azelnidipine and indapamide in this study were indirectly selected on the basis of previous reports. Azelnidipine 16 mg and amlodipine 5mg had the similar blood pressure-lowering effects. ⁶ Hydrochlorothiazide 12.5 mg and amlodipine 5 mg were used for the starting doses in combination with an angiotensin converting enzyme inhibitor. ⁷ In combination with ARB, indapamide 0.65 mg to 1.0mg and hydrochlorothiazide 12.5 mg had the comparable blood pressure-lowering effects. ⁸ The study drugs were to be taken after breakfast. Use of other antihypertensives or any drugs that might affect the evaluation of study measurements was not allowed.

The study measurements included serum OPG, serum high-sensitivity C-reactive protein (hs-CRP), matrix metalloproteinase 2 (MMP-2), and tissue inhibitor of matrix metalloproteinase (TIMP) 2. Blood samples were drawn from the cubital vein at 3 and 12 months. As the first blood pressure measurements for the analysis, we used the levels obtained 3 months after the start of the treatment. Because we intended to exclude the early antihypertensive effects on the markers, and the sufficient antihypertensive effects would have been obtained after 3 months. Latex immunonephelometry was used for the measurement of hs-CRP, and an enzyme-linked immunosorbent assay (ELISA) kit (Daiichi Fine Chemical Co, Ltd, Japan) for MMP-2 and TIMP-2 measurements. Osteoprotegerin was measured using commercial ELISA kits; OPG by Immundiagnostic AG (intra- and interassay coefficient of variation: 4.0% and 4.8%; Bensheim, Germany).

For the evaluation of arteriosclerosis, the cardio-ankle vascular index (CAVI) was determined after a 10-minute rest during an outpatient visit using the vascular screening system VaSera VS-1000 (Fukuda Denshi Co, Ltd, Japan). The patients were not allowed to eat or smoke immediately before the examination.

Results

The 32 men and 16 women in this study ranged in age from 43 to 78 (mean 68.3 ± 14.9) years and had an average body mass index (BMI) of 23.3 ± 6.4 kg/m². There were no significant differences in baseline characteristics (age, sex, BMI, blood pressure, pulse rate, cardiovascular risks, estimated glomerular filtration rate [GFR], which is calculated using the Modification of Diet in Renal Disease Study equation [GFR = 186.3 × [serum creatinine in mg/dL] − 1.154 × [age] − 0.203 × [0.742 if female]], medication usage in diabetes mellitus or hyperlipidemia) between patients treated with O/A group and those treated with the O/D group (Table 1).

OPEN IN VIEWER

Table 1.

Baseline Characteristics of the 2 Groups.

	Olmesartan/Azelnidipine, n = 24	Olmesartan/Diuretics, n = 24	P Value
Male/female	15/9	14/10	.76
Age, years	68 ± 16	68 ± 12	.64
BMI, kg/m2	23.4 ± 6.2	23.2 ± 7.1	.42
Blood pressure, mm Hg
Systolic	148 ± 8	150 ± 12	.41
Diastolic	82 ± 8	83 ± 7	.37
Pulse rate, bpm	68 ± 8	67 ± 7	.51
Coronary risk factor
DM, n (%)	9 (38)	8 (33)	.76
Dyslipidemia, n (%)	7 (30)	6 (25)	.74
Smoking, n (%)	6 (25)	4 (17)	.36
eGFR, mL/min/1.73 m2	65.8 ± 19.5	67.1 ± 15.7	.41

Abbreviations: BMI, body mass index; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate.

After 12 months of treatment, blood pressures were significantly decreased in both groups, and there was no significant intergroup difference (SBP: 18 ± 7 mm Hg and DBP: 6 ± 5 mm Hg in the O/A group; SBP: 19 ± 11 mm Hg and DBP: 8 ± 2 mm Hg in the O/D group). The pulse rate was significantly decreased in the O/A group (−4.4 ± 4.2 bpm) than in the O/D group (Table 2). Changes in blood low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol levels did not differ significantly between the 2 treatment groups (Table 2). During the follow-up period, no new onset of diabetes mellitus and worsening renal function were observed in either group.

OPEN IN VIEWER

Table 2.

Comparison of Changes in the 2 Groups.

	Olmesartan/Azelnidipine	Olmesartan/Diuretics	P Value
ΔBlood pressure, mm Hg
Systolic	−18 ± 7	−19 ± 11	.43
Diastolic	−6 ± 5	−8 ± 2	.10
ΔPulse rate, bpm	−4.4 ± 4.2	1.2 ± 2.6	.031
ΔLDL-C, mg/dL	−7 ± 15	−4 ± 22	.62
ΔHDL-C, mg/dL	1.0 ± 5.4	0.8 ± 3.6	.49

Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Serum OPG was significantly decreased at 12 months, as compared with the data at 3 months, in the O/A group (P < .05) while there was no significant reduction in the O/D group (Figure 1).

OPEN IN VIEWER

Figure 1.

Box plots for the changes in bone-rerated markers in the 2 groups. This graph shows the serum OPG: OPG levels at 3 and 12 months after treatment. Serum OPG was significantly decreased at 12 months, as compared with the data at 3 months, in the O/A group (P < .05) while there was no significant reduction in the O/D group. OPG indicates osteoprotegerin; O/A, olmesartan plus azelnidipine; O/D, olmesartan plus indapamide.

At 12 months, hs-CRP was significantly reduced as compared with the data at 3 months in the O/A group while there was no significant reduction in the O/D group (Figure 2A). Matrix metalloproteinase 2 also showed a significant decrease at 12 months as compared with the data at 3 months in the O/A group, while there was no significant change in the O/D group (Figure 2B). Cardio-ankle vascular index was significantly improved at 12 months, as compared with the data at 3 months, in both the treatment groups. The improvement was significantly greater in the O/A group than in the O/D group (Figure 3).

OPEN IN VIEWER

Figure 2.

Box plots for the changes in serum hs-CRP and serum MMP-2 levels after treatments. A, At 12 months, hs-CRP was significantly reduced as compared with the data at 3 months in the O/A group while there was no significant reduction in the O/D group. B, Matrix metalloproteinase 2 also showed significant decrease at 12 months as compared with the data at 3 months in the O/A group, while there was no significant change in the O/D group. hs-CRP indicates high-sensitive CRP; MMP-2, matrix metalloproteinase 2; O/A, olmesartan plus azelnidipine; O/D, olmesartan plus indapamide.

OPEN IN VIEWER

Figure 3.

Box plots for the changes in CAVI in the 2 groups after treatment. Cardio-ankle vascular index was significantly improved at 12 months, as compared with the data at 3 months, in both the treatment groups. The improvement was significantly greater in the O/A group than in the O/D group. CAVI indicates cardio-ankle vascular index; O/A, olmesartan plus azelnidipine; O/D, olmesartan plus indapamide.

Discussion

The major finding in this study was that serum OPG levels were significantly reduced by combination therapy in the O/A group compared to the O/D groups, despite there being no significant difference in brachial SBP decreases between these 2 groups. Although there were no intergroup differences in brachial blood pressure decreases or lipid levels, the CAVI improvement was significantly greater in the O/A group than in the O/D group.

Calcification of the abdominal aorta and carotid artery correlates with arteriosclerosis. ⁹ Recent studies have found coronary artery calcification to correlate with arteriosclerosis. ¹⁰ Vascular calcification is now regarded as an important predictor of cardiovascular events. In the present study, the bone-related marker OPG decreased in patients treated with O/A as compared with that in patients treated with O/D. Osteoprotegerin is a secretory protein belonging to the tumor necrosis factor receptor gene super family and inhibits both the induction of osteoclast differentiation and bone resorption. High serum OPG is associated with increased risk of cardiovascular death. ¹¹ Serum OPG increases in proportion to coronary calcification in type 2 diabetics. ¹² Therefore, serum OPG is considered to be very useful as a vascular calcification marker. Only a few studies have examined the effects of drug therapies on serum OPG levels. One study showed that pioglitazone reduced serum OPG and hs-CRP in type 2 diabetics. ¹³ The authors suggested that the serum OPG level may be decreased by the anti-inflammatory action of pioglitazone. Whether decreases in OPG directly reflect amelioration of vascular calcification remains uncertain. Statins and bisphosphonates are thought to reduce vascular calcification based on anti-inflammatory action as well as antioxidative action. ¹⁴ Since azelnidipine exerts both a strong anti-inflammatory action and an antioxidative action on the vascular wall, ¹⁵ the calcification inhibitory factor OPG may decrease in parallel with reduced vascular stress.

Improvements in blood pressure, lipid levels, and glucose metabolism are required to reduce the arteriosclerosis indicator CAVI. ¹⁶ In regard to antihypertensive drugs with a vasodilatory effect, both ARBs and CCBs have been shown to reduce the arterial stiffness. However, the extent of reduction in the arterial stiffness varies between the 2 classes of drugs. ^16,17 Furthermore, it has also been reported that statins reduce the arterial stiffness. ¹⁸ Thus, although antihypertensive effects may contribute to reduction in the arterial stiffness, other factors may also be important. ^19,20 . The CAVI improvement in our patients could be explained by mechanisms of action of azelnidipine other than its hemodynamic effects, because the blood pressure and lipid level reductions were unchanged compared with diuretics. One of the pharmacological characteristics of azelnidipine is high-vascular tissue affinity. Azelnidipine exerts a continuous action on vascular tissue independently of its blood concentration, and, in contrast to other CCBs, the blood pressure-lowering effect of azelnidipine is thought to be minimally associated with its elimination half-life or blood concentration. ⁴ The free radical scavenging ability to reduce systemic oxidative stress of azelnidipine is greater than that of other dihydropiridine calcium antagonists or diuretics. ^15,21,22 The intergroup difference in CAVI improvement in our study may be attributable to these antiatherogenic actions and antioxidant effects of azelnidipine. In the Japan-Combined Treatment with Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy (J-CORE) study, ²³ in which olmesartan was administered in combination with azelnidipine or hydrochlorothiazide, the aortic pulse wave velocity was measured, and significant improvement in central arterial change and arterial stiffness with combined use of olmesartan and azelnidipine has already been reported. In our study, we consider that the CAVI results were similar to those in the J-CORE study, and we speculate that changes in central arterial blood pressure may also contribute to the improvement in arterial stiffness and bone-rerated markers.